3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Solid Tumours
1
Interventions
AZD 6244
5
GSK 1363089
3
pazopanib
1
molibresib
1
ispinesib
1
enzalutamide
1
brigimadlin
1
abiraterone
1
Topotecan
1
SLC-0111
1
Rifampin
1
Prednisone
1
Omeprazole
1
Moxifloxacin
1
Midazolam
1
Itraconazole
1
Granisetron
1
Fluconazole
1
Famotidine
1
Doxorubicin
1
Cytochrome P-450 CYP3A
1
Cytochrome P-450 CYP2C19
1
Cytochrome P-450 CYP1A2
1
Carboplatin
1
Carbon-14
1
Caffeine
1
CH5183284
1
BGC945
1
2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Solid Tumours
×
BGC945
×
Clear all
NCT02360345
2024-09-26
ONX-0801
Royal Marsden NHS Foundation Trust
Phase 1
Completed
111 enrolled